Aurobindo Pharma Subsidiaries Receive Mixed FDA Inspection Results with VAI Classification for API Facility
核心洞察
Aurobindo Pharma's API manufacturing subsidiary Apitoria Pharma received a Voluntary Action Indicated (VAI) classification from the US FDA (搜索), indicating successful resolution of previous warning letter issues.
The FDA concluded its for-cause inspection of the Telangana facility with five procedural observations, determining that corrective actions adequately addressed prior regulatory concerns.
A separate formulations facility operated by subsidiary Eugia Pharma Specialities (搜索) in Rajasthan received nine procedural observations following a November inspection.
Aurobindo Pharma announced that its active pharmaceutical ingredient manufacturing subsidiary has successfully resolved regulatory concerns with the US Food and Drug Administration, receiving a Voluntary Action Indicated (VAI) classification following a comprehensive inspection process. The development marks a significant regulatory milestone for the Indian pharmaceutical company's API operations.
API Facility Receives VAI Classification
The FDA issued an establishment inspection report classifying Unit I of Apitoria Pharma Private Limited, located in Sangareddy district, Telangana, as VAI. This classification indicates that while objectionable conditions or practices were found, the regulator is not prepared to take or recommend any administrative or regulatory action.
The facility had previously received a warning letter from the FDA in January 2022, which prompted a for-cause inspection conducted from August 21-29, 2025. Following this inspection, the FDA issued Form 483 with five observations, which the company described as "procedural in nature" with no data integrity issues reported.
"The US FDA (搜索) has since completed evaluation of the corrective actions. It has determined the issues cited in the warning letter and Form 483 have been adequately addressed," Aurobindo Pharma stated in its regulatory filing.
Formulations Unit Faces New Observations
In a separate development, Aurobindo Pharma's formulations subsidiary Eugia Pharma Specialities (搜索) received nine observations from the FDA following an inspection of its Unit-II facility in Bhiwadi, Alwar, Rajasthan. The inspection was conducted from November 3-14, 2025.
The company characterized these observations as "procedural in nature" and confirmed they will be responded to within the stipulated timeframe. Aurobindo Pharma emphasized that "the development will not have any impact on existing operations of the unit."
Regulatory Context and Classifications
The VAI classification is one of three possible outcomes from FDA inspections. VAI indicates that objectionable conditions were found but the agency is not prepared to take regulatory action. The other classifications include No Action Indicated (NAI), which means no objectionable conditions were found, and Official Action Indicated (OAI), which recommends regulatory and administrative actions.
The positive resolution of the API facility's regulatory status represents a significant development for Aurobindo Pharma's manufacturing operations. Following the announcement, Aurobindo Pharma shares closed 1.08% higher on Friday at ₹1,221.90 each on the BSE, reflecting investor confidence in the regulatory progress.